65
Participants
Start Date
September 30, 2013
Primary Completion Date
September 30, 2017
Study Completion Date
September 30, 2017
TAS-102
Escalating doses (20-35 mg/m2/dose, based on tolerability), orally, twice daily on days 1-5 of each 14-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
CPT-11
Escalating doses (30-minute infusion of 120-180 mg/m2/dose, based on tolerability), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Bevacizumab
Dose (infusion of 5 mg/kg administered per site standard practice), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Memorial Sloan-Kettering Cancer Center, New York
Vanderbilt Ingram Cancer Center, Nashville
Chicago Clinical Site, Chicago
Los Angeles Clinical Site, Los Angeles
Taiho Oncology, Inc.
INDUSTRY